LEADER 05412nam 22007455 450 001 9910300331703321 005 20200629215319.0 010 $a88-470-2679-2 024 7 $a10.1007/978-88-470-2679-7 035 $a(CKB)3710000000075606 035 $a(EBL)1593291 035 $a(SSID)ssj0001067121 035 $a(PQKBManifestationID)11691169 035 $a(PQKBTitleCode)TC0001067121 035 $a(PQKBWorkID)11079544 035 $a(PQKB)11765217 035 $a(MiAaPQ)EBC1593291 035 $a(DE-He213)978-88-470-2679-7 035 $a(PPN)176127011 035 $a(EXLCZ)993710000000075606 100 $a20131127d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAdherence to Antipsychotics in Schizophrenia /$fby Emilio Sacchetti, Antonio Vita, Alberto Siracusano, Wolfgang Fleischhacker 205 $a1st ed. 2014. 210 1$aMilano :$cSpringer Milan :$cImprint: Springer,$d2014. 215 $a1 online resource (168 p.) 300 $aDescription based upon print version of record. 311 $a88-470-2678-4 320 $aIncludes bibliographical references and index. 327 $a1 Poor adherence to antipsychotic medication in people with schizophrenia: diffusion, consequences, and contributing factors -- Premise -- Role of antipsychotics in the treatment of schizophrenia -- Compliance versus adherence -- Assessment of medication adherence -- Frequency of poor adherence to antipsychotics -- Consequences of poor adherence to antipsychotics -- Determinants and moderators of adherence to antipsychotics -- Present and medium-term perspectives -- Closing Remarks -- 2 Pharmacological strategies to enhance adherence in schizophrenia -- Introduction -- Pharmacological factors contributing to non-adherence: efficacy, side effects, regimen, co-therapies -- First vs Second generation antipsychotics: efficacy, tolerability and the adherence issue -- Long-acting injectable antipsychotics -- Conclusion. 3 Non-pharmacological strategies to enhance adherence and continuity of care in schizophrenia -- Introduction -- Factors Influencing (non-)adherence in Schizophrenia -- Interventions to Enhance Adherence. Research and Clinical Evidence -- Comprehensive Review of Psychosocial and Programmatic Interventions to Enhance Adherence to Antipsychotic Medication in Schizophrenia -- Summary of Main Results and Evidences -- Conclusions and Future Directions -- 4 Psychological issues in improving adherence and alliance -- The patient-doctor relationship as a determinant of adherence to treatment -- Alliance and psychodynamic issues -- Towards the concept of concordance of the therapeutic project. 330 $aPoor adherence to therapy is one of the main obstacles to treatment effectiveness in schizophrenia. It is the main determinant of relapse, hospitalization, symptom persistence, and poor psychosocial functioning and outcome. Adherence to treatment is affected by various factors related to the disease characteristics, to the patient him- or herself, to the treatment, and to the therapeutic relationship. Some of these factors are modifiable, and both pharmacological and non-pharmacological strategies have been developed for this purpose. This book addresses the different aspects of adherence to treatment in schizophrenia and related disorders in a systematic but easy-to-use manual format. Chapters focus on a full range of issues, including pharmacological and non-pharmacological strategies to enhance adherence and continuity of care, relevant psychological factors, the importance of the patient-doctor relationship, and the need for an alliance with other care-givers. Adherence to Antipsychotics in Schizophrenia will be an invaluable asset for all who are involved in the care of patients with schizophrenia. 606 $aPsychiatry 606 $aPsychopharmacology 606 $aPsychotherapy    606 $aNeurosciences 606 $aPharmacology 606 $aPsychiatry$3https://scigraph.springernature.com/ontologies/product-market-codes/H53003 606 $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010 606 $aPsychotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H5400X 606 $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aPsychiatry. 615 0$aPsychopharmacology. 615 0$aPsychotherapy   . 615 0$aNeurosciences. 615 0$aPharmacology. 615 14$aPsychiatry. 615 24$aPsychopharmacology. 615 24$aPsychotherapy. 615 24$aNeurosciences. 615 24$aPharmacology/Toxicology. 676 $a615/.7882 676 $a616.89806 700 $aSacchetti$b Emilio$4aut$4http://id.loc.gov/vocabulary/relators/aut$01065289 702 $aVita$b Antonio$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aSiracusano$b Alberto$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aFleischhacker$b Wolfgang$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910300331703321 996 $aAdherence to Antipsychotics in Schizophrenia$92544366 997 $aUNINA